FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
BECONASE AQ
beclomethasone dipropionate monohydrate
LOE Approaching
GSK
NASAL · SPRAY, METERED
recurrence of nasal polyps following surgical removal
1987
NDA30/100
BENADRYL
diphenhydramine hydrochloride
LOE Approaching
Johnson & Johnson
ORAL · CAPSULE
these symptoms due to hay feverother upper respiratory allergies: runny nose sneezing itchy+2
1946
NDA30/100
BENADRYL
diphenhydramine hydrochloride
LOE Approaching
Johnson & Johnson
INJECTION · INJECTABLE
these symptoms due to hay feverother upper respiratory allergies: runny nose sneezing itchy+2
1947
NDA30/100
BENADRYL PRESERVATIVE FREE
diphenhydramine hydrochloride
LOE Approaching
Johnson & Johnson
INJECTION · INJECTABLE
1957
NDA30/100
BENDAMUSTINE HYDROCHLORIDE
bendamustine hydrochloride
Launch
Dr. Reddy's Laboratories
INTRAVENOUS · SOLUTION
within six months of treatment with rituximaba rituximab-containing regimen+2
2025
NDA30/100
BENDAMUSTINE HYDROCHLORIDE
bendamustine hydrochloride
Peak
INTRAVENOUS · SOLUTION
within six months of treatment with rituximaba rituximab-containing regimen+1
2022
NDA30/100
BENDAMUSTINE HYDROCHLORIDE
bendamustine hydrochloride
Peak
Pfizer
INTRAVENOUS · SOLUTION
within six months of treatment with rituximaba rituximab-containing regimen+2
2022
NDA30/100
BENDAMUSTINE HYDROCHLORIDE
bendamustine hydrochloride
Peak
Baxter
INTRAVENOUS · SOLUTION
within six months of treatment with rituximaba rituximab-containing regimen+2
2022
NDA30/100
BENDECTIN
doxylamine succinate; pyridoxine hydrochloride
LOE Approaching
Sanofi
ORAL · TABLET, EXTENDED RELEASE
cough due to minor throatbronchial irritation+3
1956
NDA30/100
BENEMID
probenecid
LOE Approaching
Merck & Co.
ORAL · TABLET
uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coliKlebsiella pneumoniae+7
1951
NDA30/100
BENICAR
olmesartan medoxomil
LOE Approaching
ORAL · TABLET
hypertension in adultolder+5
2002
NDA30/100
BENICAR HCT
olmesartan medoxomil-hydrochlorothiazide
LOE Approaching
ORAL · TABLET
hypertensionto lower blood pressure+1
2003
NDA30/100
BENOQUIN
monobenzone
LOE Approaching
Bausch + Lomb
TOPICAL · CREAM
1952
NDA30/100
BENSULFOID
sulfur
LOE Approaching
TOPICAL · POWDER
1940
NDA30/100
BENTYL
dicyclomine hydrochloride
LOE Approaching
AbbVie
INJECTION · INJECTABLE
functional bowel/irritable bowel syndrome ()
1952
NDA30/100
BENTYL
dicyclomine hydrochloride
LOE Approaching
AbbVie
ORAL · CAPSULE
functional bowel/irritable bowel syndrome ()
1950
NDA30/100
BENTYL
dicyclomine hydrochloride
LOE Approaching
ORAL · SYRUP
functional bowel/irritable bowel syndrome ()
1951
NDA30/100
BENTYL PRESERVATIVE FREE
dicyclomine hydrochloride
LOE Approaching
AbbVie
INJECTION · INJECTABLE
functional bowel/irritable bowel syndrome ()
1952
NDA30/100
BENZACLIN
benzoyl peroxide; clindamycin phosphate
LOE Approaching
Bausch + Lomb
TOPICAL · GEL
2000
NDA30/100
BENZAMYCIN
erythromycin and benzoyl peroxide
LOE Approaching
Bausch + Lomb
TOPICAL · GEL
1984
NDA30/100
BENZNIDAZOLE
benznidazole
Peak
ORAL · TABLET
caused by Trypanosoma cruzi ( )
2017
SMNDA30/100
BEPADIN
bepridil hydrochloride
LOE Approaching
Bausch Health
ORAL · TABLET
1990
NDA30/100
BEPREVE
bepotastine besilate
LOE Approaching
Bausch + Lomb
OPHTHALMIC · SOLUTION/DROPS
itching associated with signssymptoms of allergic conjunctivitis+1
2009
NDA30/100
BEROCCA PN
ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a palmitate; vitamin e
LOE Approaching
Roche
INJECTION · INJECTABLE
1947
NDA30/100